2013—2017年广东省男性前列腺癌流行特征及趋势

目的 分析广东省2013—2017年男性前列腺癌流行特征及趋势。方法 使用2013—2017年广东省肿瘤登记数据，采用SAS 9.4软件及Joinpoint 4.8.0.1软件，按照地区、年龄组分层计算前列腺癌发病和死亡的粗率(CR)、中国人口标化率(ASRC)、世界人口标化率(ASRW)、年度变化百分比(APC)。结果 广东省2013—2017年男性前列腺癌平均粗发病率、中标率及世标率分别为13.52/10万、10.40/10万及10.13/10万；五年间的死亡中标率和世标率呈下降趋势，APC分别为-3.4%和-2.9%(P<0.05);2013—2017年65岁及以上年龄组平均粗发病率和粗死亡率分别高达134.93/10万及53.24/10万，粗死亡率呈逐年下降趋势，APC为-2.8%(P<0.05);五年间城市地区平均粗发病率(14.59/10万)及平均粗死亡率(6.29/10万)均高于农村地区的平均粗发病率(10.82/10万)及平均粗死亡率(4.08/10万)。结论 2013—2017年间广东省男性前列腺癌发病水平较为稳定，死亡中标率和世标率呈下降趋势；前列腺癌发...

Epidemiological characteristics and trend of prostate cancer among men in Guangdong, 2013-2017

Objective To analyze the epidemiological characteristics and trends of male prostate cancer in Guangdong Province from 2013 to 2017. Methods Based on the cancer registry data of Guangdong Province from 2013 to 2017, the crude rate(CR)of prostate cancer incidence and mortality, age-standardized rate by Chinese standard population in 2000(ASRC), age-standardized rate by Segi's world population(ASRW)and annual percentage change(APC)were analyzed by SAS 9.4 Sofeuare and Joinpoint 4.8.0.1 according to the region and age group. Results The average crude incidence rate, bid winning rate and world standard rate of male prostate cancer in Guangdong Province from 2013 to 2017 were 13.52/10⁵, 10.40/10⁵ and 10.13/10⁵ respectively. The ASRC and ASRW of mortality showed a downward trend in the five years, and the APC was -3.4% and -2.9% respectively(P<0.05). From 2013 to 2017, the average crude incidence rate and crude mortality of the age group 65 years old and above reached 134.93/10⁵ and 53.24/10⁵ respectively, and the crude mortality rate showed a downward trend year by year, with APC of -2.8%(P<0.05). The average crude incidence rate(14.59/10⁵)and average crude mortality(6.29/10⁵)in urban areas during the five years were higher than the average crude incidence rate(10.82/10⁵)and average crude mortality(4.08/10⁵)in rural areas. Conclusion The incidence of prostate cancer in men in Guangdong Province was relatively stable from 2013 to 2017, while then ASRC and ASRW of mortality showed a downward trend. The incidence and death of prostate cancer are mainly concentrated in the age group 65 years and older.